Advances in Drug Delivery for Eye Diseases

The human eye presents one of the most elegant drug delivery challenges in medicine: a small, highly compartmentalized organ protected by biological barriers specifically evolved to keep foreign substances out. Conventional eye drops — still the most prescribed delivery method — lose an estimated 95% of their active ingredient to tear drainage, blinking, and nasolacrimal absorption before the drug reaches its target tissue (National Eye Institute). That inefficiency drives the search for delivery systems that can place therapeutics precisely where they are needed and keep them there long enough to matter.

The Problem with Eye Drops

Topical drops remain the frontline treatment for glaucoma, dry eye disease, and post-surgical inflammation. Yet adherence rates for glaucoma patients hover around 50% at one year, according to data reviewed by the American Academy of Ophthalmology (AAO). The reasons are predictable: complex dosing schedules, stinging on application, and the simple manual difficulty of aiming a drop into one's own eye. For diseases of the posterior segment — age-related macular degeneration (AMD), diabetic macular edema, retinal vein occlusion — topical drops are largely ineffective because the drug cannot penetrate deeply enough to reach the retina.

This gap between what drops can do and what patients need has catalyzed research across sustained-release implants, nanoparticle carriers, gene therapy vectors, and port delivery systems.

Sustained-Release Implants

Intravitreal implants bypass the anterior barriers entirely by placing a drug reservoir directly inside the vitreous cavity. The FDA approved the dexamethasone intravitreal implant (Ozurdex, Allergan) in 2009 for macular edema following retinal vein occlusion, with the biodegradable polymer releasing corticosteroid over roughly four to six months (FDA). A non-biodegradable fluocinolone acetonide implant (Yutiq, EyePoint Pharmaceuticals) followed in 2018, designed to deliver drug for up to 36 months for chronic non-infectious uveitis affecting the posterior segment (FDA).

For glaucoma, the bimatoprost sustained-release implant (Durysta) received FDA approval in 2020 as the first intracameral implant for open-angle glaucoma or ocular hypertension, offering intraocular pressure reduction for months from a single administration — effectively removing the daily drop burden (FDA).

The Port Delivery System

Anti-VEGF injections transformed the treatment of wet AMD after ranibizumab and aflibercept reached the market, but the standard regimen involves intravitreal injections every four to eight weeks — a schedule that strains patients, caregivers, and retina clinics alike. The port delivery system with ranibizumab (Susvimo, Genentech) addressed this directly: a surgically implanted refillable reservoir that continuously releases ranibizumab into the vitreous. Clinical trial data (the Archway study) showed non-inferiority to monthly injections, with refills needed only every six months (National Library of Medicine). The FDA approved Susvimo in October 2021, though Genentech later voluntarily withdrew it from the market in late 2023 citing manufacturing challenges — a reminder that even promising delivery platforms face practical hurdles beyond clinical efficacy.

Nanoparticle and Mucoadhesive Systems

The next frontier for topical delivery involves engineering at the nanoscale. Nanoparticles — lipid-based, polymeric, or dendrimer-based — can enhance corneal penetration, extend drug residence time on the ocular surface, and protect sensitive biologics from degradation. Research funded through the National Institutes of Health has explored mucoadhesive nanoparticles that bind to the mucin layer of the tear film, resisting the rapid washout that defeats conventional drops (NIH Reporter).

A specific example: polymeric nanoparticles using poly(lactic-co-glycolic acid), or PLGA, have demonstrated sustained release of drugs like dexamethasone and timolol in preclinical models, with some formulations maintaining therapeutic concentrations for two to four weeks from a single topical application. While commercial products based on these platforms are still navigating clinical trials, the underlying science has matured considerably, with multiple Phase II studies underway as cataloged on ClinicalTrials.gov.

Gene Therapy as a Delivery Paradigm

Gene therapy reframes "delivery" entirely: rather than repeatedly supplying a drug molecule, a one-time procedure delivers genetic instructions that enable cells to produce the therapeutic protein themselves. Voretigene neparvovec (Luxturna), approved by the FDA in 2017 for biallelic RPE65 mutation-associated retinal dystrophy, demonstrated this concept in practice — a single subretinal injection of an adeno-associated virus (AAV) vector carrying a functional copy of the RPE65 gene (FDA). It was the first directly administered gene therapy approved in the United States.

Research programs at institutions including the Casey Eye Institute at Oregon Health & Science University and the Scheie Eye Institute at the University of Pennsylvania are exploring AAV-delivered anti-VEGF gene therapies for wet AMD, which could theoretically replace indefinite injection schedules with a single treatment.

What Comes Next

Emerging approaches include suprachoroidal injection — delivering drug into the space between the sclera and choroid, targeting the posterior segment while avoiding the vitreous. The FDA approved triamcinolone acetonide for suprachoroidal injection (Xipere, Clearside Biomedical) in 2021 for macular edema associated with uveitis (FDA). This route may open a less invasive path for retinal drug delivery without the risks of intravitreal procedures.

Microneedle patches, hydrogel-forming contact lenses, and light-activated drug release systems represent earlier-stage research. The throughline across all of these technologies is the same: reducing treatment burden while maintaining or improving the concentration of drug at the target tissue.

The eye, for all its protective barriers, is becoming a proving ground for some of the most sophisticated delivery engineering in medicine.

References

• National Eye Institute — Eye Conditions and Diseases
• American Academy of Ophthalmology — Improving Glaucoma Medication Adherence
• FDA — Ozurdex Label
• FDA — Yutiq Label
• FDA — Durysta Approval Announcement
• Archway Trial — PubMed
• NIH Reporter
• ClinicalTrials.gov
• FDA — Luxturna
• FDA — Xipere Label

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)